Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs FTAI Aviation Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while FTAI Aviation Ltd trades at $224.9 (market cap $23.33B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and FTAI Aviation Ltd pays a 0.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FTAI | |
|---|---|---|
Market Cap | $39.89B | $23.33B |
Sector | Health | Industrials |
52-Week High | $491.22 | $310.04 |
52-Week Low | $278.09 | $109.92 |
Enterprise Value | $38.15B | $26.37B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FTAI Aviation trades at $227.35, down 0.29% on the day, with a bearish technical signal despite strong analyst consensus. The company reported Q1 2026 EPS of $1.29, missing expectations of $1.50, but maintains robust revenue growth and a net income margin of 18.92%. Recent strategic collaborations and a dividend increase to $0.45 highlight management's confidence in long-term prospects, particularly in aerospace services and data center power solutions.
Outlook remains positive driven by aerospace demand and innovation in power solutions, though risks include earnings misses and high valuation multiples. With 100% buy ratings from analysts and institutional support, the stock offers growth potential but requires monitoring of execution against forecasts and competitive pressures in evolving markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
